Value through InnovationJanuary 27 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States


Boehringer Ingelheim and Vanderbilt University join forces
to develop new Ras inhibitors for cancer treatment


Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas


The Lancet Oncology publishes phase III data showing Gilotrif® (afatinib) extends overall survival in lung cancer patients whose tumors have the most common EGFR mutation compared with chemotherapy


New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers


Boehringer Ingelheim Receives Perfect Rating on Human Rights Campaign Foundation’s Corporate Equality Index


National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes


Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation


New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)


New Survey Uncovers Critical Need to Break Down Barriers and Improve Communication and Education about the Link between Atrial Fibrillation and Devastating Impact of Stroke

back 1 2 3 4 5 6 7 8 9 10